Compare Ally Financial Inc (ALLY) vs Alnylam Pharmaceuticals, Inc. (ALNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ally Financial Inc vs Alnylam Pharmaceuticals, Inc. — how do they compare? Ally Financial Inc trades at $43.84 (market cap $13.37B), while Alnylam Pharmaceuticals, Inc. trades at $221.99 (market cap $29.60B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.2× Ally Financial Inc's market cap, and Ally Financial Inc pays a 2.73% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALLY | ALNY | |
|---|---|---|
Market Cap | $13.37B | $29.60B |
Sector | Financials | Health |
52-Week High | $47.25 | $491.22 |
52-Week Low | $35.96 | $205.48 |
Dividend Yield | 2.73% | — |
Enterprise Value | — | $27.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ally Financial (ALLY) trades at $43.81, showing minimal daily movement. The stock exhibits a bearish technical signal with recent earnings missing estimates in Q2 2026, though revenue grew 10% year-over-year. Valuation metrics appear attractive with a P/E of 10.34 and P/B below 1. Analyst consensus remains strongly bullish with a $54.40 price target, but insider selling and mixed technical indicators suggest near-term caution.
The outlook for ALLY hinges on execution amid macroeconomic pressures. Upside potential exists from solid loan growth and digital banking strength, but risks include rising provisions, competitive pressures, and interest rate sensitivity. Earnings growth in upcoming quarters is critical for sustaining investor confidence and driving the stock toward analyst targets.
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ally Financial Inc
Ally Financial Inc is a diversified financial services firm that services automotive dealers and their retail customers. The company operates as a financial holding company and a bank holding company. Its banking subsidiary, Ally Bank, caters to the direct banking market through Internet, mobile, and mail. The company reports four business segments including Automotive Finance operations, Insurance operations, Mortgage Finance operations and Corporate Finance operations.
Read more on ALLY →About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →
